Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer

Jenny Fink1, Karl Sanders, Alexandra Rippl

  • 1Nycomed GmbH, RPD/SO, Byk-Gulden-Strasse 2, D-78467 Konstanz, Germany. .

Insights

Targeting Polo-like kinase 1 (Plk1) in cancer is promising. Inhibiting its kinase or polo box domain showed varied effects on cell growth and mitosis across different cancer types.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Biochemistry

Background:

  • Polo-like kinase 1 (Plk1) is crucial for mitosis and a target for cancer therapy.
  • Plk1 has two key domains: kinase and polo box, both involved in its function.

Purpose of the Study:

  • To compare the effects of inhibiting Plk1's kinase activity versus its polo box domain in human cancer cell lines.
  • To investigate the distinct cellular responses to these two interference strategies.

Main Methods:

  • Used a small-molecule Plk1 kinase inhibitor.
  • Employed inducible overexpression of the Plk1 polo box domain.
  • Assessed effects on cell growth, mitosis, apoptosis, and cell morphology in RKOp27, PC-3, and U2OS cells.

Main Results:

  • Plk1 polo box overexpression inhibited growth in RKOp27 and PC-3 cells, leading to multinucleation in PC-3.
  • Plk1 kinase inhibition caused mitotic arrest and apoptosis in RKOp27 cells.
  • Both strategies induced mitotic abnormalities and apoptosis in U2OS cells, with similar spindle defects.

Conclusions:

  • Interfering with Plk1's polo box or kinase domain can yield similar phenotypic outcomes in some cancer cells but contrasting effects in others.
  • These differences may reflect variations in mitosis regulation machinery across cancer cell types.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...